



FEATURES OF THE MODERN CLINICAL COURSE OF CHRONIC HEART FAILURE

Qobiljonova Shaxnoza Rustamovna

Allamberganova Jasmina Ergashevna

Odilov Shohidbek Dilmurod O'g'li

Malikjonov Ulug'bek Ilhom O'g'li

Tashkent State Medical University, Tashkent, Uzbekistan

Abstract

Relevance of the problem. Despite significant advances in the treatment of cardiovascular diseases, the prevalence of chronic heart failure (CHF) is not only not declining but is steadily increasing, with the growth in incidence resembling a non-communicable epidemic. The MONICA study, conducted on a large, unorganized population, showed a CHF prevalence of 2%. A study of city residents over 50 years of age found a CHF prevalence of up to 4%. In the EPOCH-CHF population-based study, the increase in CHF prevalence by clinical criteria was more than 4%, especially in older age groups, reaching 9.7%. According to Euro-Heart Survey Study of the main causes of CHF development consider: ischemic heart disease (IHD) - 60%, valvular heart defects - 14%, dilated cardiomyopathy - 11%. Many independent nosological forms or pathological conditions[^] are currently considered as risk factors for CHF. Identification of modifiable and non-modifiable risk factors for CHF and a modern understanding of its pathogenetic mechanisms have allowed the formation of the phenomenological concept of a "cardiovascular continuum." The essence of the phenomenon is that risk factors for coronary heart disease through hypertrophy and myocardial dysfunction of the left ventricle (LV), or through the development of Stenosing coronary atherosclerosis, myocardial ischemia, and acute myocardial infarction lead to the death and hibernation of cardiomyocytes, activation of apoptosis, and, ultimately, cardiac remodeling and the development of CHF. The characteristics of the cardiovascular continuum are that, from a certain stage of cardiac damage, the progression of myocardial



remodeling and the development of CHF occur according to general patterns independent of the etiologic factor.

An important factor in maintaining the normal functioning of the cardiovascular system is the timely prevention of the development of cardiac diseases through early and reliable determination possible risk factors for the occurrence and development of pathological changes in the myocardium. Pre-symptomatic diagnosis feasible, not only for genetic diseases but also for many multifactorial ones. The "geneticization" of medicine has led to the emergence of molecular medicine. This, in turn, has given rise to new areas of medical science, one of which is predictive medicine, which is appropriately considered the earliest stage of a person's active intervention in their body, with the goal of timely correction of a potential pathology or pathological process. When studying genes involved in the development of CHF, of primary interest is the study of gene polymorphisms of components of the SAS and RAAS systems, which play a leading role in the pathogenesis of both underlying diseases (hypertension, coronary heart disease, myocardial infarction, type 2 diabetes mellitus, etc.) and CHF itself. However, recent studies have shown that, despite improvements in the clinical condition of patients and a reduction in cardiovascular risk with the use of inhibitors of these systems, CHF continues to progress. Therefore, the influence of immune activation and systemic inflammation on the progression of CHF is currently being actively investigated. Proinflammatory cytokines are recognized as the most significant components of this activation. It has long been proven that in the development of cardiovascular diseases in general and CHF in particular, a special place is occupied by endothelial dysfunction, which participates in the development of pathology through an increase in the activity of tissue and circulating RAAS and SAS, suppression of the expression of endothelial NO-synthase, which leads to a chronic decrease in blood flow and a distortion of the vascular response to "shear stress", an increase in the level of proinflammatory cytokines, an increase in the concentration of free radicals, an increase in low-density and very low-density lipoproteins.

Currently, a whole group of genes involved in the development of CHF is being studied. These include genes encoding aldosterone synthase, angiotensin-



converting enzyme, tumor necrosis factor, adrenergic receptors, atrial natriuretic peptide, and endothelial Synthase. Data from case-control studies are highly variable. A genotype that is predominant in one population may be minor in another, making studies for each ethnic and population group unique and significant. Advances in medical science and the introduction of a huge number of new drugs do not diminish the relevance of the problems of effective and safe pharmacotherapy for patients with various cardiovascular pathologies. It is clear that one of the ways to improve the effectiveness and safety of pharmacotherapy is the introduction of so-called personalized medicine technologies into clinical practice. These technologies are based on an individual approach to the selection of drugs and their dosage regimen, taking into account factors influencing the pharmacological response and the individual characteristics of each specific patient; one of the current areas of genetic research is pharmacogenetics. A number of the largest pharmacogenetic studies have identified significant differences in the effectiveness of CHF therapy depending on the genetic characteristics of the patient. Therefore, clinical pharmacogenetics provides the opportunity to individualize the choice of IgGs and their dosage regimens based on the study of the genotype of a particular patient.

The aim of the study was to investigate the clinical and molecular genetic aspects of the neurohumoral mechanisms of initiation and development of chronic heart failure in patients with coronary artery disease to improve the effectiveness of risk stratification, prevention, and drug therapy.

Research Objectives:

1. To assess the role of genes of the neurohumoral and cytokine systems in the mechanisms of initiation of chronic heart failure of ischemic genesis in order to identify genetic determinants of increased risk of developing this pathology.
2. To identify candidate genes that determine the severity of CHF in patients with coronary heart disease.
3. During a 12-month prospective observation, study the relationship between polymorphic variants of genes and the nature of the course of CHF in patients



with coronary heart disease in order to identify early objective predictors of CHF progression.

Results of the Study

It was established for the first time that a high risk of developing CHF of ischemic genesis is associated with polymorphisms of the CT gene. In this study, a relationship between polymorphisms of the IL-1 gene and the severity of clinical manifestations of CHF in patients with ischemic heart disease was revealed for the first time. In patients with coronary heart disease, genetic determinants that determine the nature of the course of CHF were identified for the first time: predictors of an unfavorable course of pathology - the G allele and the G/G genotype of the TNF- α gene (G-308A), the C allele and the G/C genotype of the gene. As a result of this study, associations between GT polymorphisms of the IL-1 β gene and endothelial dysfunction were identified for the first time. The pharmacogenetic features of β - blockers (carvedilol and bisoprolol), AIF inhibitors (fosinopril and enalairil) in the treatment of CHF were studied . It was established that in carriers of the D/D genotype of the I/D polymorphic marker; ACE gene, treatment of CHF with fosinopril and enalapril was more effective compared to carriers of the 1/1 genotype, and homozygotes Arg / Arg polymorphisms of the Gly389Arg locus of the β_j -adrenergic receptor gene are more sensitive to carvedilol therapy than heterozygotes Gly / Arg.

The study of polymorphic loci of different groups of genes regulating neurohumoral and cytokine status and the functional state of the endothelium allows the use of genetic markers as criteria for assessing the individual prognosis of the development and course of CHF in patients with coronary heart disease.

These prognostic indicators allow us to identify high-risk groups for developing heart failure in the setting of chronic myocardial ischemia (taking into account identified gender differences) and to predict the severity and course of heart failure. This enables an individualized approach to high-tech modern diagnostics, disease prevention, and treatment based on a personalized medicine strategy aimed at improving quality of life and survival. Genetic markers have been substantiated, the typing of which is necessary for identifying patients at high risk



for developing heart failure in patients with ischemic and post-infarction myocardial dysfunction.

It is advisable to use polymorphic variants of the genes of interleukin, tumor necrosis factor, endothelial NO synthase, inducible NO synthase, aldosterone synthase, atrial natriuretic peptide, β -adrenergic receptor, angiotensinogen, angiotensin-converting enzyme (I/D) and angiotensin 2 receptor type 1 as diagnostic markers.

Polymorphisms of the genes IL-1 β with aldosterone synthase, β -adrenoreceptor predetermine neurohumoral mechanisms of initiation and formation of XGH, developed against the background of ischemic and/or post-infarction myocardial dysfunction.

In patients with coronary heart disease (CHD) with ischemic and post-infarction myocardial remodeling with systolic dysfunction; myocardium, interconnected; with CHF, an increased risk of developing; heart failure, associated with: carriage of the G allele and the G/G genotype of the G polymorphic locus of the TNF- α gene, the C allele and the C/G genotype of the CT polymorphic locus of the IL-1 β gene, the Glu and the Glu / Glu genotype, the eNOS gene polymorphic locus; alleles and the T/T polymorphic locus of the gene, ATE, the D allele and the D/D genotype of the I/D polymorphic locus, the ACE gene, the C allele and the A / C genotype of the ATP1 gene polymorphic locus.

Pathogenetic mechanisms of development of heart failure in conditions of chronic myocardial ischemia and/or post-infarction cardiac remodeling are associated with wide variability in the occurrence of genetic markers of CHF depending on gender: in men, the Glu allele and the Glu / Glu genotype of the eNOS gene, the iNOS gene allele, the D allele and the D / D genotype of the ACE gene were associated with an increased risk of developing the disease; and in women - the G allele and the A / C genotype of the gene. Polymorphisms of the TNF- α , IL-1 β , aldosterone synthase, β -adrenoreceptor, ATG genes are associated with the risk of developing CHF in conditions of chronic myocardial ischemia in both men and women.



Conclusions

In patients with CHF against the background of chronic myocardial ischemia, the severity of endothelial vasomotor function disorders depended on the FC of CHF severity. In patients with FC I CHF ($7.4 \pm 0.35\%$ and $16.5 \pm 0.29\%$) and FC II ($6.8 \pm 0.29\%$ and $15.2 \pm 0.23\%$), significantly higher levels of EZD and ENZD were determined ($p < 0.01$ and $p < 0.05$, respectively) in relation to those in patients with FC III-IV CHF ($5.5 \pm 0.19\%$ and $12.7 \pm 0.27\%$).

The severity of endothelial dysfunction is associated with polymorphisms of the studied genes in patients with coronary heart disease complicated by CHF. The most pronounced endothelial dysfunction was recorded in carriers of the C/ C genotype of the IL- 1β gene (C+3953T), the Glu / Glu genotype of the eNOS gene, alleles of the iNOS gene, the G/G genotype of the endothelin-1 gene (K148N), the Gly / Gly genotype of the β i-adrenoreceptor gene, the D/D genotype of the ACE gene (I/D) and the C/C genotype of the AT2P gene. In CHF against the background of ischemic and/or post-infarction myocardial remodeling with obvious disturbances⁴ of the inotropic function of the heart and structural changes in the LV, there is an association with the carriage of the C/ C genotype of the proinflammatory cytokine IL - 1β gene, alleles of the iNOS gene, the T/T genotype of the aldosterone synthase gene, the Gly / Gly genotype of the β i-adrenoreceptor gene, and the D/D genotype of the ACE gene (I/D).

In patients with coronary artery disease with manifested CHF, a 12-month course of therapy with carvedilol, bisoprolol, fosinopril and enalapril is effective in reducing blood pressure, decreasing heart rate and NYHA functional class of CHF, increasing LVEF and regressing ischemic remodeling of the heart against the background of wide variability in the effectiveness of the drug classes used depending on the studied genotypes - homozygotes Arg / Arg polymorphisms of the Gly389Arg locus of the β i-adrenergic receptor gene are more sensitive to carvedilol therapy than heterozygotes. Gly / Arg, and in carriers of the D/D genotype »polymorphic marker I/D of the ACE gene Treatment of CHF with fosinopril and enalapril was more effective compared to carriers of the I/I genotype.



References

1. Axmedova, P. B. (2025). ADENOTOMY IN CHILDREN WITH ALLERGIC RHINITIS AND BRONCHIAL ASTHMA. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(3), 459-466.
2. Durdona, Q. S. R. O. T. (2024). THE CURRENT STATE OF THE PROBLEM OF SEVERE ACUTE PANCREATITIS.
3. ERMATOV, N., KASSYMOVA, G., TAJIYEVA, K., KHASANOVA, M., ALIMUKHAMEDOVA, M., & AZIMOVA, S. (2020). Expression of tissue-specific genes in mice with hepatocarcinogenesis. International Journal of Pharmaceutical Research (09752366), 12(3).
4. Ikramova, N. A., Jalolov, N. N., Mirsagatova, M. R., Kasimova, K. T., Sadirova, M. K., & Sultonov, E. Y. (2025, April). AMBIENT TEMPERATURE AND THE RISK OF THERMOREGULATORY DISORDERS AMONG TRAFFIC POLICE OFFICERS: AN EPIDEMIOLOGICAL ANALYSIS. International Conference on Advance Research in Humanities, Applied Sciences and Education.
5. Inakov, S. A., Mamatkulov, B. B., Kosimova, K., Saidalikhjaeva, S., & Shoyusupova, K. B. (2020). Social and demographic characteristics of elderly and their lifestyle in developing countries: on the example of Uzbekistan. Indian Journal of Forensic Medicine & Toxicology, 14(4), 7418-7425.
6. Kamilova DN, Saydalikhjaeva SK, Abdashimov ZB, Rakhmatullaeva DM, Tadjieva XS. Employment relations and responsibilities of medical institutions workers in a pandemic in Uzbekistan. Journal of Medicine and Innovations. 2021;2(13-1).
7. Kamilova, D. N., Saydalikhjaeva, S. K., Rakhmatullaeva, D. M., Makhmudova, M. K., & Tadjieva, K. S. (2021). Professional image of a teacher and a doctor. British Medical Journal, 1(4), 4-14.
8. Kasimova, K. T. (2024). The Role Of Ecology In The Development Of Cardiovascular Diseases.
9. Khakimova, D. S., Kobiljonova, S. R., & Salomova, F. I. (2023, June). Results of hygiene assessment of food of school students. //International



-
- Scientific-Practical Conference “Only English: Advances in Medical Research and Practice Conference” 23.05. 2023.-P. 78-79.
10. Khilola, T. K. (2024). Assessment of environmental conditions in tashkent and relationship with the population suffering from cardiovascular diseases.
 11. Khudoyberganov, M., Rakhmatkarieva, F., Abdurakhmonov, E., Tojiboeva, I., & Tadjieva, K. (2022, June). Thermodynamics of water adsorption on local kaolin modified microporous sorbents. In American Institute of Physics Conference Series (Vol. 2432, No. 1, p. 050001).
 12. Kobiljonova SR, Jalolov NN, Sharipova SA, Mirsagatova MR. SPECTRUM OF CAUSE-SIGNIFICANT ALLERGENS CAUSING POLYNOSIS IN CHILDREN.
 13. Kosimova, K. T., Jalolov, N. N., & Ikramova, N. A. (2025, April). THE RELATIONSHIP BETWEEN AIR POLLUTION AND ARTERIAL HYPERTENSION
 14. Mirrahimova, M. X., Kohiljonova, S. R., & Sadullayevna, X. A. (2022). PREVALENCE AND RISK FACTORS OF ALLERGIC DISEASE IN CHILDREN.
 15. Mirzayev, M. M., & Malikov, S. G. (2025). CORONARY HEART DISEASE AND CANCER. Web of Medicine: Journal of Medicine, Practice and Nursing, 3(3), 215-224.
 16. Mirzayev, M. M., & Malikov, S. G. (2025). DISEASES OF THE POPULATION FROM THE LEVEL OF AIR POLLUTION IN REGIONAL CONDITIONS. Web of Scientists and Scholars: Journal of Multidisciplinary Research, 3(3), 104-111.
 17. Niyazova, O. A., & Mirsagatova, M. R. (2024). THE STUDY OF RISK FACTORS FOR THE DEVELOPMENT OF CARIES IN PUPILS OF THE FIRST GRADES IN SECONDARY SCHOOLS.
 18. Qosimova, X. T., Ikramova, N. A., Juraboyeva, D. N., & Mukhtorova, D. A. (2025, March). THE ADVERSE EFFECTS OF SMARTPHONES ON COGNITIVE ACTIVITY IN THE EDUCATIONAL PROCESS AND WAYS TO MITIGATE THEM. In The Conference Hub (pp. 76-79).



-
19. Sadullaeva, K. A., Sadirova, M. Q., Ikramova, N. A., & Sotivoldieva, S. A. (2025). EFFECT OF NUTRITION ON HEALTH OF SCHOOL STUDENTS.
 20. Sadullayeva, X. A., Salomova, F. I., Mirsagatova, M. R., & Kobiljonova Sh, R. (2023). Problems of Pollution of Reservoirs in the Conditions of Uzbekistan.
 21. Salomova, F. I. (2024, February). STIMULATION OF THE IMMUNE RESPONSE BY CYTOKINE PREPARATIONS AND THEIR STANDARDIZATION. European youth innovation society conference volume 1№.
 22. Salomova, F. I., & Kim, E. S. (2025). METABOLIC DISORDERS IN CHILDREN WITH GASTROENTEROLOGICAL DISEASES AND FOOD ALLERGIES. EduVision: Journal of Innovations in Pedagogy and Educational Advancements, 1(6), 495-503.
 23. Salomova, F. I., & Kosimova, H. T. (2017). RELEVANCE OF STUDYING INFLUENCE OF THE BONDS OF NITROGEN POLLUTING THE ENVIRONMENT ON HEALTH OF THE POPULATION SUFFERING CARDIOVASCULAR ILLNESSES (REPUBLIC OF UZBEKISTAN). In INTERNATIONAL SCIENTIFIC REVIEW OF
 24. Salomova, F. I., Mavlonov, A., & Abdukadirova, L. K. (2024). Talabalar o'rtasida gastritning tarqalishi va to'g'ri ovqatlanishning ahamiyati.
 25. Salomova, F. I., Mirrahimova, M. X., Sadullayeva, X. A., & Kobiljonova, S. R. (2022, November). Prediction and prevention of food allergies in children. Uzbekistan-Japan International Conference «Energy-Earth-Environment-Engineering», November 17-18, 2022, Uzbek-Japan Innovation Center of Youth, Tashkent, Uzbekistan Uzbekistan-Japan International Conference «Energy-Earth-Environment-Engineering», November 17-18, 2022, Uzbek-Japan Innovation Center of Youth, Tashkent, Uzbekistan tesis Bet 81.
 26. Salomova, F. I., Sadullaeva, H. A., Abdullaeva, D. G., & Kobilzhonova Sh, R. (2022). PREVALENCE AND RISK FACTORS OF ALLERGIC DISEASES IN CHILDREN IN HOT CLIMATIC CONDITIONS.
 27. Salomova, F. I., Sherkuziyeva, G. F., Sharipova, S. A., & Qobiljonova Sh, R. (2025). INFLUENCE OF ENVIRONMENTAL FACTORS ON THE



-
- PREVALENCE OF ALLERGIC DISEASES DISEASES. EduVision: Journal of Innovations in Pedagogy and Educational Advancements, 1(6), 451-460.
28. Sharipova, S. A., & Ikramova, N. A. (2024). CONSEQUENCES OF NOT BREASTFEEDING FOR THE MOTHER AND INFANT. Web of Medicine: Journal of Medicine, Practice and Nursing, 2(12), 273-276.
29. Sharipova, S. A., Ikramova, N. A., Bahridinov, M. N., Toshpulatov, B. M., & Egamberdiyeva, Z. Z. (2025, March). SPECIFIC ASPECTS OF PREVENTION OF INFECTIOUS DISEASES. International Conference on Advance Research in Humanities, Applied Sciences and Education.
30. Абдукадирова, Л. К. (1999). Бир ёшгача бўлган болалар соғлиқ ҳолатига ижтимоий-гигиеник ва экологик омилларнинг таъсири. кандидатлик диссертацияси. кандидатлик диссертацияси.
31. Абдукадирова, Л. К. (2017). Соғлом турмуш тарзининг гигиеник асослари. Фан ва техника тараққиётида хотин-қизларнинг ўрни. Республика илмий-амалий анжумани маърузалар тўплами.
32. Абдукадирова, Л. К. Она ва бола саломатлиги-миллат соғлиги. Тиббий таълимда инновацияларни қўллаш ва интеграл маърузаларни такомиллаштириш-2016 С96-97, 3.
33. Абдукадирова, Л. К., & Абдуллаева, Ў. Я. (2019). Тошкент шаҳри кичик ёшдаги болалар тарбияланаётган оилаларнинг ижтимоий-гигиеник ҳолатини ўрганиш натижалари. Интернаука, (5-2), 47-48.
34. Абдукадирова, Л. К., & Абдурахмонов, Б. О. (2019). РАДИОЛОГИЯ БЎЛИМИ ХОНАЛАРИДАГИ НУРЛАНИШ ДОЗА ДАРАЖАСИНИ АНИҚЛАБ БАҲОЛАШ. Интернаука, (3-3), 30-31.
35. Абдукадирова, Л. К., & Умирбеков, О. Д. (2020). Даволаш профилактика муассасалари радиология бўлими хоналаридаги нурланиш доза даражасини аниқлаб баҳолаш. Интернаука, (2-2), 68-69.
36. Абдукадирова, Л. К., Турсинбаев, А. А., & Халиуратов, Б. З. (2021). ЭКОЛОГИК МУАММОЛАР-ИЖТИМОЙ СИЁСАТНИНГ АЖРАЛМАС ҚИСМИ. Интернаука, (1-3), 36-37.
-



-
37. Абдукадырова, Л. К., Иброхимова, Д. И., & Гуломова, Ш. Х. (2023). ВЛИЯНИЕ БЕССОННИЦЫ НА ПСИХОЭМОЦИОНАЛЬНОЕ СОСТОЯНИЕ СТУДЕНТОВ. In Proceedings of International Conference on Educational Discoveries and Humanities (Vol. 2, No. 3, pp. 151-155).
 38. Ахмадалиева, Н. О., Саломова, Ф. И., Садуллаева, К. А., Абдукадилова, Л. К., & Имамова, А. О. (2024). ИЗЪЯТО: Питание часто болеющих детей дошкольного возраста в организованных коллективах. В BIO Web of Conferences (т. 84, стр. 01011). EDP Sciences.
 39. Ахмадалиев, Ю. И., & Комилова, Н. Ё. (2020). Этноэкологик маданиятнинг худудий жихатлари.
 40. Закирходжаев, Ш. Я., Жалолов, Н. Н., Абдукадилова, Л. К., & Мирсагатова, М. Р. (2023). ЗНАЧЕНИЕ ПИТАНИЯ ПРИ ХРОНИЧЕСКИХ ГЕПАТИАХ.
 41. Икрамова, Н.А., Мирсагатова, М.Р., Джалолов, Н.Н., Касимова, К.Т., Султонов, Э.Ю., и Садирова, М.К. (2025, апрель). ВЛИЯНИЕ ТЕПЛОВОЙ НАГРУЗКИ НА ОРГАНИЗМ РАБОТНИКОВ, РАБОТАЮЩИХ НА ОТКРЫТОМ ВОЗДУХЕ: АНАЛИЗ ПО МЕДИКО-ГИГИЕНИЧЕСКИМ ПОКАЗАТЕЛЯМ. Международная конференция по перспективным исследованиям в области гуманитарных, прикладных наук и образования.
 42. Кобилжонова ШР, Садуллаева ХА. IMPACTS OF THE ENVIRONM ENT ON HUMAN HEALTH.
 43. Кобилжонова, Ш. Р. (2024). CLINICAL AND MORPHOLOGICAL FEATURES OF GASTRODUODENITIS IN CHILDREN WITH SALINE DIATHESIS.
 44. КОБИЛЖОНОВА, Ш., ТОШЕВА, Ш., & ЗОКИРЖОНОВА, Г. (2023). Modern approaches to diet therapy for food allergies in children.
 45. Миррахимова, М. Х., Садуллаева, Х. А., & Кобилжонова, Ш. Р. (2022). Значение экологических факторов при бронхиальной астме у детей (Doctoral dissertation, Россия).
 46. Мирсагатова, М. Р. (2017). Особенности трудового процесса при производстве хрусталя. Молодой ученый, (1-2), 34-35.



-
47. Саломова ФИ, Ахмадалиева НО, Кобилжонова ШР. Избыточный вес и ожирение у детей: ключевые факторы.
 48. Саломова ФИ, Кобилжонова ШР. Оценка эффективности диетотерапии при пищевой аллергии у детей в различные возрастные периоды. Вестник ТМА SPECIAL ISSUE Dedicated to The 10th International Symposium On Important Problems of the Environmental Protection and Human Health.
 49. Саломова, Ф. И., & Кобилжонова, Ш. Р. (2024). Факторы риска аллергических заболеваний у детей дошкольного возраста.
 50. Саломова, Ф. И., & Кобилжонова, Ш. Р. (2024, March). РАЗРАБОТКА СИСТЕМНЫХ АЛГОРИТМОВ СНИЖЕНИЯ АЛЛЕРГИЧЕСКИХ ЗАБОЛЕВАНИЙ. Международный форум «ANaMed Forum–New Generation 2025» Алматы: КазНМУ, 2025..
 51. Саломова, Ф. И., & Кобилжонова, Ш. Р. (2024, May). ФАКТОРЫ РИСКА РАЗВИТИЯ АЛЛЕРГИИ У ДЕТЕЙ. Международный форум «ANaMed Forum–New Generation 2025» Алматы: КазНМУ, 2025.-С. 1154-1155.